KR102668608B1 - 조작된 crispr-cas9 뉴클레아제 - Google Patents

조작된 crispr-cas9 뉴클레아제 Download PDF

Info

Publication number
KR102668608B1
KR102668608B1 KR1020187008311A KR20187008311A KR102668608B1 KR 102668608 B1 KR102668608 B1 KR 102668608B1 KR 1020187008311 A KR1020187008311 A KR 1020187008311A KR 20187008311 A KR20187008311 A KR 20187008311A KR 102668608 B1 KR102668608 B1 KR 102668608B1
Authority
KR
South Korea
Prior art keywords
artificial sequence
dna
spcas9
lys
description
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187008311A
Other languages
English (en)
Korean (ko)
Other versions
KR20180042394A (ko
Inventor
제이. 키쓰 종
벤자민 클레인스티버
비크람 패타나야크
Original Assignee
더 제너럴 하스피탈 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/015,947 external-priority patent/US9512446B1/en
Application filed by 더 제너럴 하스피탈 코포레이션 filed Critical 더 제너럴 하스피탈 코포레이션
Priority to KR1020247016635A priority Critical patent/KR20240090567A/ko
Publication of KR20180042394A publication Critical patent/KR20180042394A/ko
Application granted granted Critical
Publication of KR102668608B1 publication Critical patent/KR102668608B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020187008311A 2015-08-28 2016-08-26 조작된 crispr-cas9 뉴클레아제 Active KR102668608B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247016635A KR20240090567A (ko) 2015-08-28 2016-08-26 조작된 crispr-cas9 뉴클레아제

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562211553P 2015-08-28 2015-08-28
US62/211,553 2015-08-28
US201562216033P 2015-09-09 2015-09-09
US62/216,033 2015-09-09
US201562258280P 2015-11-20 2015-11-20
US62/258,280 2015-11-20
US201562271938P 2015-12-28 2015-12-28
US62/271,938 2015-12-28
US15/015,947 US9512446B1 (en) 2015-08-28 2016-02-04 Engineered CRISPR-Cas9 nucleases
US15/015,947 2016-02-04
PCT/US2016/049147 WO2017040348A1 (en) 2015-08-28 2016-08-26 Engineered crispr-cas9 nucleases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247016635A Division KR20240090567A (ko) 2015-08-28 2016-08-26 조작된 crispr-cas9 뉴클레아제

Publications (2)

Publication Number Publication Date
KR20180042394A KR20180042394A (ko) 2018-04-25
KR102668608B1 true KR102668608B1 (ko) 2024-05-24

Family

ID=58188120

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187008311A Active KR102668608B1 (ko) 2015-08-28 2016-08-26 조작된 crispr-cas9 뉴클레아제
KR1020247016635A Pending KR20240090567A (ko) 2015-08-28 2016-08-26 조작된 crispr-cas9 뉴클레아제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247016635A Pending KR20240090567A (ko) 2015-08-28 2016-08-26 조작된 crispr-cas9 뉴클레아제

Country Status (8)

Country Link
EP (2) EP3341477B1 (enExample)
JP (6) JP6799586B2 (enExample)
KR (2) KR102668608B1 (enExample)
CN (2) CN108350449B (enExample)
AU (2) AU2016316845B2 (enExample)
CA (1) CA2996888A1 (enExample)
HK (1) HK1257676A1 (enExample)
WO (1) WO2017040348A1 (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9885033B2 (en) 2013-03-15 2018-02-06 The General Hospital Corporation Increasing specificity for RNA-guided genome editing
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
ES2888976T3 (es) 2014-06-23 2022-01-10 Massachusetts Gen Hospital Identificación no sesgada pangenómica de DSBs evaluada por secuenciación (GUIDE-Seq.)
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP4464338A3 (en) 2014-11-07 2025-02-12 Editas Medicine, Inc. Systems for improving crispr/cas-mediated genome-editing
WO2016141224A1 (en) 2015-03-03 2016-09-09 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
JP7030522B2 (ja) 2015-05-11 2022-03-07 エディタス・メディシン、インコーポレイテッド 幹細胞における遺伝子編集のための最適化ｃｒｉｓｐｒ／ｃａｓ９システムおよび方法
CN108026526B (zh) 2015-06-09 2023-05-12 爱迪塔斯医药公司 用于改善移植的crispr/cas相关方法和组合物
KR102668608B1 (ko) * 2015-08-28 2024-05-24 더 제너럴 하스피탈 코포레이션 조작된 crispr-cas9 뉴클레아제
CN108350453A (zh) 2015-09-11 2018-07-31 通用医疗公司 核酸酶dsb的完全查询和测序(find-seq)
AU2016326711B2 (en) 2015-09-24 2022-11-03 Editas Medicine, Inc. Use of exonucleases to improve CRISPR/Cas-mediated genome editing
CA3000762A1 (en) 2015-09-30 2017-04-06 The General Hospital Corporation Comprehensive in vitro reporting of cleavage events by sequencing (circle-seq)
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and their uses
WO2017165826A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
EP4047092B1 (en) 2016-04-13 2025-07-30 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20230164759A (ko) * 2016-10-07 2023-12-04 인티그레이티드 디엔에이 테크놀로지스 아이엔씨. Ｓ. 피오게네스 ｃａｓ９ 돌연변이 유전자 및 이에 의해 암호화되는 폴리펩티드
JP7588390B2 (ja) 2016-10-14 2024-11-22 プレジデント アンド フェローズ オブ ハーバード カレッジ 核酸塩基エディターのａａｖ送達
WO2018119010A1 (en) 2016-12-19 2018-06-28 Editas Medicine, Inc. Assessing nuclease cleavage
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US12110545B2 (en) 2017-01-06 2024-10-08 Editas Medicine, Inc. Methods of assessing nuclease cleavage
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
BR112019019655A2 (pt) 2017-03-23 2020-04-22 Harvard College editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico
CN110799525A (zh) 2017-04-21 2020-02-14 通用医疗公司 具有改变的PAM特异性的CPF1(CAS12a)的变体
CN108795989A (zh) * 2017-04-26 2018-11-13 哈尔滨工业大学 SpyCas9的基因编辑活性抑制位点及其抑制剂
EP3615672A1 (en) 2017-04-28 2020-03-04 Editas Medicine, Inc. Methods and systems for analyzing guide rna molecules
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
JP7324713B2 (ja) 2017-05-25 2023-08-10 ザ ジェネラル ホスピタル コーポレイション 改善された精度および特異性を有する塩基エディター
KR102746733B1 (ko) * 2017-06-09 2024-12-24 에디타스 메디신, 인코포레이티드 조작된 cas9 뉴클레아제
KR102691097B1 (ko) * 2017-07-07 2024-08-02 주식회사 툴젠 표적 특이적 crispr 변이체
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
WO2019040650A1 (en) 2017-08-23 2019-02-28 The General Hospital Corporation GENETICALLY MODIFIED CRISPR-CAS9 NUCLEASES HAVING MODIFIED PAM SPECIFICITY
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
JP6628387B2 (ja) * 2017-09-05 2020-01-08 国立大学法人 東京大学 改変されたＣａｓ９タンパク質及びその用途
US20190218532A1 (en) * 2017-09-19 2019-07-18 Massachusetts Institute Of Technology Streptococcus Canis Cas9 as a Genome Engineering Platform with Novel PAM Specificity
EP3694993A4 (en) 2017-10-11 2021-10-13 The General Hospital Corporation SITE-SPECIFIC AND PARASITIC GENOMIC DESAMINATION DETECTION METHODS INDUCED BY BASIC EDITING TECHNOLOGIES
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
WO2019157326A1 (en) 2018-02-08 2019-08-15 Zymergen Inc. Genome editing using crispr in corynebacterium
CN109306361B (zh) * 2018-02-11 2022-06-28 华东师范大学 一种新的a/t到g/c碱基定点转换的基因编辑系统
WO2019204378A1 (en) 2018-04-17 2019-10-24 The General Hospital Corporation Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
AU2019291918B2 (en) 2018-06-29 2025-06-12 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
JP2021524272A (ja) 2018-07-10 2021-09-13 エーエルアイエー セラピューティクス エス． アール． エル． ガイドｒｎａ分子および／またはガイドｒｎａ分子／ｒｎａ誘導型ヌクレアーゼ複合体の無痕跡送達のための小胞およびその産生方法
CN112955549B (zh) * 2018-09-19 2024-12-20 香港大学 改进的高通量组合基因修饰系统和优化的Cas9酶变体
CN109265562B (zh) * 2018-09-26 2021-03-30 北京市农林科学院 一种切刻酶及其在基因组碱基替换中的应用
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020163396A1 (en) 2019-02-04 2020-08-13 The General Hospital Corporation Adenine dna base editor variants with reduced off-target rna editing
WO2020186059A2 (en) * 2019-03-12 2020-09-17 Crispr Therapeutics Ag Novel high fidelity rna-programmable endonuclease systems and uses thereof
EP3942042A1 (en) 2019-03-19 2022-01-26 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
EP3956349A1 (en) 2019-04-17 2022-02-23 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12351838B2 (en) 2019-04-26 2025-07-08 Toolgen Incorporated Target-specific CRISPR mutant
CN110272881B (zh) * 2019-06-29 2021-04-30 复旦大学 核酸内切酶SpCas9高特异性截短变异体TSpCas9-V1/V2及其应用
CN110577969B (zh) * 2019-08-08 2022-07-22 复旦大学 CRISPR/Sa-SlugCas9基因编辑系统及其应用
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
AU2020402526B2 (en) * 2019-12-10 2025-01-23 Inscripta, Inc. Novel MAD nucleases
WO2021121321A1 (zh) * 2019-12-18 2021-06-24 华东师范大学 一种提高基因编辑效率的融合蛋白及其应用
CN112979822B (zh) * 2019-12-18 2022-11-15 华东师范大学 一种疾病动物模型的构建方法及融合蛋白
US12312613B2 (en) 2020-01-24 2025-05-27 The General Hospital Corporation Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants
US12264341B2 (en) 2020-01-24 2025-04-01 The General Hospital Corporation CRISPR-Cas enzymes with enhanced on-target activity
AU2021219795A1 (en) 2020-02-12 2022-08-25 Massachusetts Eye And Ear Infirmary Haplotype-based treatment of RP1 associated retinal degenerations
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US20230313159A1 (en) * 2020-07-26 2023-10-05 Asc Therapeutics, Inc. Variants of cas nuclease
GB202019908D0 (en) * 2020-12-16 2021-01-27 Oxford Genetics Ltd Cripr polypeptides
CN112538471B (zh) * 2020-12-28 2023-12-12 南方医科大学 一种CRISPR SpCas9(K510A)突变体及其应用
CN112680430B (zh) * 2020-12-28 2023-06-06 南方医科大学 一种CRISPR SpCas9突变体及其应用
EP4326864A4 (en) * 2021-04-22 2025-06-18 Emendobio Inc. OMNI-17,140, 150-158,160-165,167-177,180-188,1921-92,205-201,215-201,221,2222,2236,239,229,239,285,245,26R
US20230279442A1 (en) * 2021-12-15 2023-09-07 Versitech Limited Engineered cas9-nucleases and method of use thereof
CA3244527A1 (en) 2022-02-18 2023-08-24 Dana-Farber Cancer Institute, Inc. CELL SURFACE RECEPTOR EPITOPE MODIFICATION
CN117384880A (zh) * 2022-07-08 2024-01-12 北京干细胞与再生医学研究院 工程化的核酸修饰编辑器
CN118956820B (zh) * 2024-05-10 2025-09-09 中国人民解放军军事科学院军事医学研究院 一种Cas9蛋白突变体及在基因编辑技术中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140068797A1 (en) 2012-05-25 2014-03-06 University Of Vienna Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2341149T3 (en) 2005-08-26 2017-02-27 Dupont Nutrition Biosci Aps Use of CRISPR-associated genes (Cas)
RU2531343C2 (ru) 2007-03-02 2014-10-20 ДюПон Ньютришн Байосайенсиз АпС, Способ генерирования заквасочной культуры, заквасочная культура и способ ферментации с ее использованием
FR2925918A1 (fr) 2007-12-28 2009-07-03 Pasteur Institut Typage et sous-typage moleculaire de salmonella par identification des sequences nucleotidiques variables des loci crispr
WO2010011961A2 (en) 2008-07-25 2010-01-28 University Of Georgia Research Foundation, Inc. Prokaryotic rnai-like system and methods of use
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
US9404098B2 (en) 2008-11-06 2016-08-02 University Of Georgia Research Foundation, Inc. Method for cleaving a target RNA using a Cas6 polypeptide
MX337838B (es) 2008-11-07 2016-03-22 Dupont Nutrition Biosci Aps Secuencias de repetidos palindromicos cortos regularmente intercalados agrupados de bifidobacterias.
WO2010066907A1 (en) 2008-12-12 2010-06-17 Danisco A/S Genetic cluster of strains of streptococcus thermophilus having unique rheological properties for dairy fermentation
US10087431B2 (en) 2010-03-10 2018-10-02 The Regents Of The University Of California Methods of generating nucleic acid fragments
CN103038338B (zh) 2010-05-10 2017-03-08 加利福尼亚大学董事会 核糖核酸内切酶组合物及其使用方法
EA201390586A1 (ru) 2010-10-20 2014-11-28 ДюПон НЬЮТРИШН БАЙОСАЙЕНСИЗ АпС Последовательности crispr-cas lactococcus
WO2012164565A1 (en) 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions and methods for downregulating prokaryotic genes
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
SG10201606959PA (en) 2012-02-24 2016-09-29 Hutchinson Fred Cancer Res Compositions and methods for the treatment of hemoglobinopathies
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
US9102936B2 (en) 2012-06-11 2015-08-11 Agilent Technologies, Inc. Method of adaptor-dimer subtraction using a CRISPR CAS6 protein
EP2674501A1 (en) 2012-06-14 2013-12-18 Agence nationale de sécurité sanitaire de l'alimentation,de l'environnement et du travail Method for detecting and identifying enterohemorrhagic Escherichia coli
US9258704B2 (en) 2012-06-27 2016-02-09 Advanced Messaging Technologies, Inc. Facilitating network login
WO2014071235A1 (en) 2012-11-01 2014-05-08 Massachusetts Institute Of Technology Genetic device for the controlled destruction of dna
EP3138911B1 (en) 2012-12-06 2018-12-05 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
ES2536353T3 (es) 2012-12-12 2015-05-22 The Broad Institute, Inc. Ingeniería de sistemas, métodos y composiciones de guía optimizadas para manipulación de secuencias
CN105658796B (zh) 2012-12-12 2021-10-26 布罗德研究所有限公司 用于序列操纵的crispr-cas组分系统、方法以及组合物
CN113355357B (zh) 2012-12-12 2024-12-03 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
EP3064585B1 (en) 2012-12-12 2020-02-05 The Broad Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
ES2701749T3 (es) 2012-12-12 2019-02-25 Broad Inst Inc Métodos, modelos, sistemas y aparatos para identificar secuencias diana para enzimas Cas o sistemas CRISPR-Cas para secuencias diana y transmitir resultados de los mismos
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
EP2931898B1 (en) 2012-12-12 2016-03-09 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
BR112015013784A2 (pt) 2012-12-12 2017-07-11 Massachusetts Inst Technology aplicação, manipulação e otimização de sistemas, métodos e composições para manipulação de sequência e aplicações terapêuticas
CN105074061B (zh) 2012-12-13 2021-03-09 美国陶氏益农公司 位点特异性核酸酶活性的dna检测方法
DK3553174T3 (da) 2012-12-17 2025-08-04 Harvard College Rna-guided modificering af humant genom
NZ629569A (en) 2013-01-14 2018-07-27 Recombinetics Inc Hornless livestock
US20140212869A1 (en) 2013-01-25 2014-07-31 Agilent Technologies, Inc. Nucleic Acid Proximity Assay Involving the Formation of a Three-way junction
EP2954042B1 (en) 2013-02-07 2017-12-06 The General Hospital Corporation Tale transcriptional activators
US10660943B2 (en) 2013-02-07 2020-05-26 The Rockefeller University Sequence specific antimicrobials
EP2958996B1 (en) 2013-02-25 2019-10-16 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
EP2922393B2 (en) 2013-02-27 2022-12-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Gene editing in the oocyte by cas9 nucleases
US10612043B2 (en) 2013-03-09 2020-04-07 Agilent Technologies, Inc. Methods of in vivo engineering of large sequences using multiple CRISPR/cas selections of recombineering events
US20140315985A1 (en) 2013-03-14 2014-10-23 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
US9885033B2 (en) 2013-03-15 2018-02-06 The General Hospital Corporation Increasing specificity for RNA-guided genome editing
WO2014144155A1 (en) 2013-03-15 2014-09-18 Regents Of The University Of Minnesota Engineering plant genomes using crispr/cas systems
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
UA121197C2 (uk) 2013-04-05 2020-04-27 Доу Агросайенсіс Ллс Нуклеаза "цинкові пальці" для модифікацїї гена ahas та спосіб її використання
US20150056629A1 (en) 2013-04-14 2015-02-26 Katriona Guthrie-Honea Compositions, systems, and methods for detecting a DNA sequence
SG10201808935WA (en) 2013-04-16 2018-11-29 Regeneron Pharma Targeted modification of rat genome
JP2016518142A (ja) 2013-05-10 2016-06-23 サンガモ バイオサイエンシーズ， インコーポレイテッド ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法および組成物
US11414695B2 (en) 2013-05-29 2022-08-16 Agilent Technologies, Inc. Nucleic acid enrichment using Cas9
US20150067922A1 (en) 2013-05-30 2015-03-05 The Penn State Research Foundation Gene targeting and genetic modification of plants via rna-guided genome editing
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
JP6482546B2 (ja) 2013-07-19 2019-03-13 ラリクス・バイオサイエンス・リミテッド・ライアビリティ・カンパニーＬａｒｉｘ Ｂｉｏｓｃｉｅｎｃｅ， Ｌｌｃ 二重対立遺伝子ノックアウトを生成するための方法および組成物
WO2015021426A1 (en) 2013-08-09 2015-02-12 Sage Labs, Inc. A crispr/cas system-based novel fusion protein and its application in genome editing
KR102829712B1 (ko) 2013-08-29 2025-07-10 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Hiv 감염증의 rna-유도 치료를 위한 방법 및 조성물
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
JP6174811B2 (ja) 2013-12-11 2017-08-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ゲノムの標的改変のための方法及び組成物
WO2015089486A2 (en) * 2013-12-12 2015-06-18 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
JP2017501149A (ja) 2013-12-12 2017-01-12 ザ・ブロード・インスティテュート・インコーポレイテッド 粒子送達構成成分を用いた障害及び疾患の標的化のためのｃｒｉｓｐｒ−ｃａｓ系及び組成物の送達、使用及び治療適用
US20150191744A1 (en) 2013-12-17 2015-07-09 University Of Massachusetts Cas9 effector-mediated regulation of transcription, differentiation and gene editing/labeling
AU2014370416B2 (en) 2013-12-26 2021-03-11 The General Hospital Corporation Multiplex guide RNAs
WO2015138510A1 (en) 2014-03-10 2015-09-17 Editas Medicine., Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
MA41349A (fr) * 2015-01-14 2017-11-21 Univ Temple Éradication de l'herpès simplex de type i et d'autres virus de l'herpès associés guidée par arn
TWI813532B (zh) * 2015-06-18 2023-09-01 美商博得學院股份有限公司 降低脱靶效應的ｃｒｉｓｐｒ酶突變
KR102668608B1 (ko) 2015-08-28 2024-05-24 더 제너럴 하스피탈 코포레이션 조작된 crispr-cas9 뉴클레아제
WO2017081288A1 (en) * 2015-11-11 2017-05-18 Lonza Ltd Crispr-associated (cas) proteins with reduced immunogenicity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140068797A1 (en) 2012-05-25 2014-03-06 University Of Vienna Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NATURE 23 July 2015 Vol 523 No 7561 Pages 481-485.
Nature 28 January 2016 Vol 529 No 7587 Pages 490-495.

Also Published As

Publication number Publication date
AU2016316845A1 (en) 2018-03-22
JP2023145657A (ja) 2023-10-11
EP4036236A1 (en) 2022-08-03
JP2018525019A (ja) 2018-09-06
KR20240090567A (ko) 2024-06-21
CN108350449A (zh) 2018-07-31
AU2022203146A1 (en) 2022-06-02
EP3341477A1 (en) 2018-07-04
AU2022203146B2 (en) 2024-08-29
AU2016316845B2 (en) 2022-03-10
EP3341477A4 (en) 2019-07-10
JP6799586B2 (ja) 2020-12-16
JP6942848B2 (ja) 2021-09-29
CN114875012B (zh) 2025-02-18
JP2021003110A (ja) 2021-01-14
WO2017040348A1 (en) 2017-03-09
CA2996888A1 (en) 2017-03-09
JP7731943B2 (ja) 2025-09-01
JP7326391B2 (ja) 2023-08-15
EP3341477B1 (en) 2022-03-23
JP6745391B2 (ja) 2020-08-26
JP7074827B2 (ja) 2022-05-24
JP2022023028A (ja) 2022-02-07
CN114875012A (zh) 2022-08-09
KR20180042394A (ko) 2018-04-25
JP2020010695A (ja) 2020-01-23
JP2021040644A (ja) 2021-03-18
HK1257676A1 (zh) 2019-10-25
CN108350449B (zh) 2022-05-31

Similar Documents

Publication Publication Date Title
KR102668608B1 (ko) 조작된 crispr-cas9 뉴클레아제
US11060078B2 (en) Engineered CRISPR-Cas9 nucleases
US10633642B2 (en) Engineered CRISPR-Cas9 nucleases
US12173339B2 (en) Variants of Cpf1 (Cas12a) with altered PAM specificity
JP7585373B2 (ja) 変更ＰＡＭ特異性を有する遺伝子操作ＣＲＩＳＰＲ－Ｃａｓ９ヌクレアーゼ
KR102210700B1 (ko) 아데노신 디아미나아제를 이용한 염기 교정 확인 방법

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180323

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210819

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230712

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240220

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240520

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240521

End annual number: 3

Start annual number: 1

PG1601 Publication of registration